Intravacc and Celonic Group will further design, develop, and produce a Covid-19 vaccine based on an immunogenic Spike (S) protein of SARS-CoV-2. The product is combined with Intravacc’s proprietary Outer Membrane Vesicle (OMV) technology.
Read all the articles in our archive by becoming a member of Innovation Origins. Sign up here as a supporter of independent journalism!
Become a member!
On Innovation Origins you can read the latest news about the world of innovation every day. We want to keep it that way, but we can't do it alone! Are you enjoying our articles and would you like to support independent journalism? Become a member and read our stories guaranteed ad-free.